PCR-Detectable Nonneoplastic Bcl-2/IgH Rearrangements Are Common in Normal Subjects and Cancer Patients at Diagnosis but Rare in Subjects Treated With Chemotherapy
- 1 April 2003
- journal article
- abstracts
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (7) , 1398-1403
Abstract
Purpose: To assess whether nonneoplastic Bcl-2/IgH rearrangements act as a confounding factor in the setting of minimal residual disease analysis by evaluating their incidence in a panel of lymphoma-free subjects, including cancer-free donors and chemotherapy-naive and chemotherapy-treated cancer patients. Patients and Methods: A total of 501 nonlymphoma subjects have been assessed: 258 cancer-free patients and 243 patients with malignancies other than lymphoma, 112 of whom were chemotherapy-naive. Patients were primarily assessed by nested polymerase chain reaction (PCR), followed by real-time quantitative PCR if they scored positive. In addition, six initially PCR-positive cancer-free donors were prospectively reassessed by qualitative and quantitative PCR after 30 and 60 days. Results: The overall incidence of Bcl-2/IgH positivity was 9.6%, with a median number of 11 rearrangements per 1,000,000 diploid genomes (range, 0 to 2,845 rearrangements), as assessed by real-time PCR. The incidence was similar in healthy subjects and cancer patients at diagnosis (12% and 12.5%; P = not significant). In contrast, the incidence of this translocation was only 2.3% in chemotherapy-treated patients (P < .001). In addition, three initially PCR-positive cancer-free donors showed persistence of their rearrangements when assessed after 30 and 60 days. Conclusion: The low incidence of nonneoplastic Bcl-2/IgH rearrangements following chemotherapy provides further evidence of the prognostic role of persistent PCR-positivity in the posttreatment molecular follow-up of follicular lymphoma patients.Keywords
This publication has 22 references indexed in Scilit:
- High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO)Blood, 2002
- Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphomaBlood, 2002
- Low frequency of BCL-2/JH translocation in peripheral blood lymphocytes of healthy Japanese individualsBlood, 2001
- Frequency of the Bcl-2/IgH Rearrangement in Normal Individuals: Implications for the Monitoring of Disease in Patients With Follicular LymphomaJournal of Clinical Oncology, 2001
- Novel 5′ Exonuclease-Based Real-Time PCR Assay for the Detection of t(14;18)(q32;q21) in Patients with Follicular LymphomaThe American Journal of Pathology, 1998
- Quantification of t(14;18) in the lymphocytes of healthy adult humans as a possible biomarker for environmental exposures to carcinogensCarcinogenesis, 1996
- BCL2 translocation frequency rises with age in humans.Proceedings of the National Academy of Sciences, 1994
- Immunologic Purging of Marrow Assessed by PCR before Autologous Bone Marrow Transplantation for B-Cell LymphomaNew England Journal of Medicine, 1991
- Avoiding false positives with PCRNature, 1989
- Mechanism of the t(14;18) chromosomal translocation: structural analysis of both derivative 14 and 18 reciprocal partners.Proceedings of the National Academy of Sciences, 1987